

# Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps

NCT06850805

---

Status	RECRUITING
Phase	Phase 3
Sponsor	Optinose US Inc.
Enrollment	84 participants

## Key Eligibility Criteria

---

### Inclusion (33)

- Male or female subjects aged 12 to 17 years, inclusive, at time of Visit 1 (Screening)
- Female subjects, if sexually active, must:
  - be practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method [e.g., condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel], or male partner sterilization) before entry and throughout the study, or
  - be surgically sterile, (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy), or
  - be abstinent.

... and 28 more (see full listing online)

### Exclusion (22)

- Females who are pregnant or lactating.
- Inability to have each nasal cavity examined for any reason, including nasal septum deviation.
- Inability to achieve bilateral nasal airflow.
- Is currently taking XHANCE®.
- Have previously used XHANCE for more than 1 month and did not achieve an adequate symptomatic response.

... and 17 more (see full listing online)

## Locations (21 total)

---

San Tan Allergy & Asthma, Gilbert, Arizona, United States  
Children's Hospital of Orange County, Orange, California, United States  
DaVinci Research, LLC, Sacramento, California, United States

... and 18 more locations